Profiling Epidermal Growth Factor Receptor and Heregulin Receptor 3 Heteromerization Using Receptor Tyrosine Kinase Heteromer Investigation Technology

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ayoub, Mohammed Akli ^a,c   See, Heng B ^a   Seeber, Ruth M ^a   Armstrong, Stephen P ^a   Pfleger, Kevin D G ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Dimerix Bioscience Pty Ltd   (Australia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; PROTEIN TYROSINE KINASE;

ARTICLE; BINDING SITE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CARBOXY TERMINAL SEQUENCE; CHEMICAL REACTION; COMPLEX FORMATION; HETEROMERIZATION; INHIBITION KINETICS; LIGAND BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BINDING SITES; FLUORESCENCE RESONANCE ENERGY TRANSFER; GRB2 ADAPTOR PROTEIN; HEK293 CELLS; HUMANS; KINETICS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TYRPHOSTINS;

EID: 84877919007     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064672     Document Type: Article

References (53)

1. Kamath S, Buolamwini JK, (2006) Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 26: 569-594.
2. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
3. Hynes NE, MacDonald G, (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
4. Linggi B, Carpenter G, (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16: 649-656.
5. Olayioye MA, Neve RM, Lane HA, Hynes NE, (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167.
6. Way TD, Lin JK, (2005) Role of HER2/HER3 co-receptor in breast carcinogenesis. Future Oncol 1: 841-849.
7. Freeman MR, (2004) HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR? Cancer Cell 6: 427-428.
8. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, et al. (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275.
9. Klapper LN, Kirschbaum MH, Sela M, Yarden Y, (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79.
10. Zhang Q, Park E, Kani K, Landgraf R, (2012) Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc Natl Acad Sci U S A 109: 13237-13242.
11. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, et al. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887.
12. Liu P, Sudhaharan T, Koh RM, Hwang LC, Ahmed S, et al. (2007) Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. Biophys J 93: 684-698.
13. Tao RH, Maruyama IN, (2008) All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 121: 3207-3217.
14. Bjorkelund H, Gedda L, Barta P, Malmqvist M, Andersson K, (2011) Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with (1)(2)(5)I-EGF. PLoS One 6: e24739.
15. Clayton AH, Orchard SG, Nice EC, Posner RG, Burgess AW, (2008) Predominance of activated EGFR higher-order oligomers on the cell surface. Growth Factors 26: 316-324.
16. Clayton AH, Walker F, Orchard SG, Henderson C, Fuchs D, et al. (2005) Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem 280: 30392-30399.
17. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, et al. (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467.
18. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, et al. (1997) Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16: 4938-4950.
19. Zhang K, Sun J, Liu N, Wen D, Chang D, et al. (1996) Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271: 3884-3890.
20. Banappagari S, Corti M, Pincus S, Satyanarayanajois S, (2012) Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. J Biomol Struct Dyn 30: 594-606.
21. Earp HS, Dawson TL, Li X, Yu H, (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115-132.
22. Berger MB, Mendrola JM, Lemmon MA, (2004) ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 569: 332-336.
23. Campbell MR, Amin D, Moasser MM, (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16: 1373-1383.
24. Sierke SL, Cheng K, Kim HH, Koland JG, (1997) Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 322 (Pt 3): 757-763.
25. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J, (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A 106: 21608-21613.
26. Kamath AV, Lu D, Gupta P, Jin D, Xiang H, et al. (2012) Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 69: 1063-1069.
27. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, et al. (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20: 472-486.
28. Ayoub MA, Pfleger KD, (2010) Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. Curr Opin Pharmacol 10: 44-52.
29. Mustafa S, See HB, Seeber RM, Armstrong SP, White CW, et al. (2012) Identification and profiling of novel alpha1A-adrenoceptor-CXC chemokine receptor 2 heteromer. J Biol Chem 287: 12952-12965.
30. Mustafa S, Pfleger KD, (2011) G protein-coupled receptor heteromer identification technology: identification and profiling of GPCR heteromers. J Lab Autom 16: 285-291.
31. See HB, Seeber RM, Kocan M, Eidne KA, Pfleger KD, (2011) Application of G protein-coupled receptor-heteromer identification technology to monitor beta-arrestin recruitment to G protein-coupled receptor heteromers. Assay Drug Dev Technol 9: 21-30.
32. Porrello ER, Pfleger KD, Seeber RM, Qian H, Oro C, et al. (2011) Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles. Cell Signal 23: 1767-1776.
33. Watts AO, van Lipzig MM, Jaeger WC, Seeber RM, van Zwam M, et al. (2013) Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br J Pharmacol 168: 1662-1674.
34. Pfleger KD, Dromey JR, Dalrymple MB, Lim EM, Thomas WG, et al. (2006) Extended bioluminescence resonance energy transfer (eBRET) for monitoring prolonged protein-protein interactions in live cells. Cell Signal 18: 1664-1670.
35. Pfleger KD, Eidne KA, (2006) Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 3: 165-174.
36. Johnstone EK, Pfleger KD, (2012) Receptor-Heteromer Investigation Technology and its application using BRET. Front Endocrinol (Lausanne) 3: 101.
37. Osherov N, Levitzki A, (1994) Epidermal-growth-factor-dependent activation of the src-family kinases. Eur J Biochem 225: 1047-1053.
38. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, et al. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517.
39. Liu P, Cleveland TE IV, Bouyain S, Byrne PO, Longo PA, et al. (2012) A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci U S A 109: 10861-10866.
40. Choi BK, Cai X, Yuan B, Huang Z, Fan X, et al. (2012) HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways. Protein Cell 3: 781-789.
41. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J, (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
42. Kim HH, Sierke SL, Koland JG, (1994) Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem 269: 24747-24755.
43. Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC, (1994) ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14: 3550-3558.
44. Suenaga A, Takada N, Hatakeyama M, Ichikawa M, Yu X, et al. (2005) Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J Biol Chem 280: 1321-1326.
45. Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, et al. (2012) The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-gamma1 signalling in breast cancer cell migration and dissemination. J Pathol 227: 234-244.
46. Carraway KL 3rd, Soltoff SP, Diamonti AJ, Cantley LC, (1995) Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 270: 7111-7116.
47. Vijapurkar U, Cheng K, Koland JG, (1998) Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase. J Biol Chem 273: 20996-21002.
48. Shankaran H, Wiley HS, Resat H, (2006) Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys J 90: 3993-4009.
49. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, et al. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287.
50. Gamett DC, Pearson G, Cerione RA, Friedberg I, (1997) Secondary dimerization between members of the epidermal growth factor receptor family. J Biol Chem 272: 12052-12056.
51. Zhang Y, Opresko L, Shankaran H, Chrisler WB, Wiley HS, et al. (2009) HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol 10: 78.
52. Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, et al. (2007) Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci 98: 1498-1503.
53. Britten CD, (2004) Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3: 1335-1342.